Synthesis and biological evaluation (in Vitro and in Vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αvβ3

Journal of Medicinal Chemistry

Volumn 55, Issue 23, 2012, Pages 10460-10474

  Colombo, Raffaele ^a   Mingozzi, Michele ^a   Belvisi, Laura ^a   Arosio, Daniela ^b   Piarulli, Umberto ^c   Carenini, Nives ^d   Perego, Paola ^d   Zaffaroni, Nadia ^d   De Cesare, Michelandrea ^d   Castiglioni, Vittoria ^a   Scanziani, Eugenio ^a   Gennari, Cesare ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CISPLATIN; CPD 11; CYCLO[DIKETOPIPERAZINE F2 ARGINYLGLYCYLASPARTIC ACID]PACLITAXEL; CYCLO[DIKETOPIPERAZINE F3 ARGINYLGLYCYLASPARTIC ACID]; CYCLO[DIKETOPIPERAZINE F3 ARGINYLGLYCYLASPARTIC ACID]PACLITAXEL; CYCLO[DIKETOPIPERAZINE F4 ARGINYLGLYCYLASPARTIC ACID]PACLITAXEL; CYCLO[DIKETOPIPERAZINE F6 ARGINYLGLYCYLASPARTIC ACID]PACLITAXEL; PACLITAXEL; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MITOSIS; MOUSE; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OLIGOPEPTIDES; PACLITAXEL; PEPTIDOMIMETICS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84870974922     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301058f     Document Type: Article

References (65)

1. Broxterman, H. J.; Lankelma, J.; Hoekman, K. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences Drug Resist. Updates 2003, 6, 111-127
2. Siepmann, J.; Siegel, R. A.; Rathbone, M. J. Fundamentals and Applications of Controlled Release Drug Delivery; Springer: New York, 2012; pp 493-516.
3. Lammers, T.; Kiessling, F.; Hennink, W. E.; Storm, G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Controlled Release 2012, 161, 175-187
4. Kratz, F.; Müller, I. A.; Ryppa, C.; Warnecke, A. Prodrug strategies in anticancer chemotherapy ChemMedChem 2008, 3, 20-53
5. Low, P. S. The optimal strategy for drug targeting Mol. Pharmacol. 2007, 4, 629-630
6. Aina, O. H.; Liu, R. W.; Sutcliffe, J. L.; Marik, J.; Pan, C. X.; Lam, K. S. From combinatorial chemistry to cancer-targeting peptides Mol. Pharmacol. 2007, 4, 631-651
7. Ruoslahti, E.; Bhatia, S. N.; Sailor, M. J. Targeting of drugs and nanoparticles to tumors J. Cell Biol. 2010, 188, 759-768
8. Mahato, R.; Tai, W.; Cheng, K. Prodrugs for improving tumor targetability and efficiency Adv. Drug Delivery Rev. 2011, 63, 659-670
9. Lu, X.; Lu, D.; Scully, M.; Kakkar, V. The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy Perspect. Med. Chem. 2008, 2, 57-73
10. Barczyk, M.; Carracedo, S.; Gullberg, D. Integrins Cell Tissue Res. 2010, 339, 269-280
11. Hynes, R. O. Integrins: bidirectional, allosteric signaling machines Cell 2002, 110, 673-687
12. Shimaoka, M.; Springer, T. A. Therapeutic antagonists and conformational regulation of integrin function Nat. Rev. Drug Discovery 2003, 2, 703-716
13. Rathinam, R.; Alahari, S. K. Important role of integrins in the cancer biology Cancer Metastasis Rev. 2010, 29, 223-237
14. Plow, E. F.; Haas, T. A.; Zhang, L.; Loftus, J.; Smith, J. W. Ligand binding to integrins J. Biol. Chem. 2000, 275, 21785-21788
15. 3 integrin antagonists J. Med. Chem. 1999, 42, 3033-3040
16. Gottschalk, K. E.; Kessler, H. The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction Angew. Chem., Int. Ed. 2002, 41, 3967-3774
17. Mas-Moruno, C.; Rechenmacher, F.; Kessler, H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation Anti-Cancer Agents Med. Chem. 2010, 10, 753-768
18. 3 in complex with an Arg-Gly-Asp ligand Science 2002, 296, 151-155
19. 3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides Curr. Med. Chem. 2010, 17, 1255-1299
20. Ressurreicao, A. S. M.; Vidu, A.; Civera, M.; Belvisi, L.; Potenza, D.; Manzoni, L.; Ongeri, S.; Gennari, C.; Piarulli, U. Cyclic RGD-peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands Chem.-Eur. J. 2009, 15, 12184-12188
21. Marchini, M.; Mingozzi, M.; Colombo, R.; Guzzetti, I.; Belvisi, L.; Vasile, F.; Potenza, D.; Piarulli, U.; Arosio, D.; Gennari, C. Cyclic RGD-peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands Chem.-Eur. J. 2012, 18, 6195-6207
22. Reynolds, A. R.; Hart, I. R.; Watson, A. R.; Welti, J. C.; Silva, R. G.; Robinson, S. D.; Da Violante, G.; Gourlaouen, M.; Salih, M.; Jones, M. C.; Jones, D. T.; Saunders, G.; Kostourou, V.; Perron-Sierra, F.; Norman, J. C.; Tucker, G. C.; Hodivala-Dilke, K. M. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors Nat. Med. 2009, 15, 392-400
23. Weis, S. M.; Stupack, D. G.; Cheresh, D. A. Agonizing integrin antagonists? Cancer Cell 2009, 15, 359-361
24. Shabbir, S. H.; Eisenberg, J. L.; Mrksich, M. An inhibitor of a cell adhesion receptor stimulates cell migration Angew. Chem., Int. Ed. 2010, 49, 7706-7709
25. Robinson, S. D.; Hodivala-Dilke, K. M. The role of β3-integrins in tumor angiogenesis: context is everything Curr. Opin. Cell Biol. 2011, 23, 630-637
26. Chen, K.; Chen, X. Integrin targeted delivery of chemotherapeutics Theranostics 2011, 1, 189-200
27. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 1998, 279, 377-80
28. Kim, J. W.; Lee, H. S. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model Int. J. Mol. Med. 2004, 14, 529-535
29. Burkhart, D. J.; Kalet, B. T.; Coleman, M. P.; Post, G. C.; Koch, T. H. Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin Mol. Cancer Ther. 2004, 3, 1593-604
30. 3 Bioconjugate Chem. 2008, 19, 1414-22
31. Mukhopadhyay, S.; Barnés, C. M.; Haskel, A.; Short, S. M.; Barnes, K. R.; Lippard, S. J. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature Bioconjugate Chem. 2008, 19, 39-49
32. Dal Pozzo, A.; Ni, M. H.; Esposito, E.; Dallavalle, S.; Musso, L.; Bargiotti, A.; Pisano, C.; Vesci, L.; Bucci, F.; Castorina, M.; Fodera, R.; Giannini, G.; Aulicino, C.; Penco, S. Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation Bioorg. Med. Chem. Lett. 2010, 18, 64-72
33. Alloatti, D.; Giannini, G.; Vesci, L.; Castorina, M.; Pisano, C.; Badaloni, E.; Cabri, W. Camptothecins in tumor homing via an RGD sequence mimetic Bioorg. Med. Chem. Lett. 2012, 22, 6509-6512
34. Chen, X.; Plasencia, C.; Hou, Y.; Neamati, N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery J. Med. Chem. 2005, 48, 1098-106 (corrigendum
35. J. Med. Chem. 2005, 48, 5874
36. Cao, Q.; Li, Z.-B.; Chen, K.; Wu, Z.; He, L.; Neamati, N.; Chen, X. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1489-98
37. 3 Int. J. Pharm. 2009, 368, 89-97
38. Marchini, M.; Mingozzi, M.; Colombo, R.; Gennari, C.; Durini, M.; Piarulli, U. Selective O -acylation of unprotected N -benzylserine methyl ester and O, N -acyl transfer in the formation of cyclo[Asp-Ser] diketopiperazines Tetrahedron 2010, 66, 9528-9531
39. Choi, H.; Aldrich, J. V. Comparison of methods for the Fmoc solid-phase synthesis and cleavage of a peptide containing both tryptophan and arginine Int. J. Pept. Protein Res. 1993, 42, 58-63
40. Deutsch, H. M.; Glinski, J. A.; Hernandez, M.; Haugwitz, R. D.; Narayanan, V. L.; Suffness, M.; Zalkow, L. H. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of Taxol with potent antitumor activity J. Med. Chem. 1989, 32, 788-792
41. Buchegger, F.; Kosinski, M.; Viertl, D.; Poitry-Yamate, C.; Baechler, S.; Prior, J. Tumor localization and mouse-derived dosimetry projection for Ga-68-NODAGA-RGD PET J. Nucl. Med. Meet. Abstr. 2011, 52, 1487
42. Ye, Y.; Zhu, L.; Ma, Y.; Niu, G.; Chen, X. Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging Bioorg. Med. Chem. Lett. 2011, 21, 1146-1150
43. 3 integrin expression Mol. Imaging Biol. 2010, 12, 530-538
44. 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis Anticancer Res. 2006, 26, 431-434
45. 68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice Bioconjugate Chem. 2011, 22, 2415-2422
46. 18F]-fluoromethylbenzoate-labeled dimeric RGD peptide for imaging tumor integrin expression Amino Acids 2012, 43, 1349-1357
47. 3 integrin binding peptides in a nude mouse model Cancer Res. 2002, 62, 6146-6151
48. 3 integrin in glioblastoma xenografts Contrast Media Mol. Imaging 2011, 6, 449-458
49. Haubner, R.; Schmitt, W.; Hö1lzemann, G.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Cyclic RGD peptides containing β-turn mimetics J. Am. Chem. Soc. 1996, 118, 7881-7891
50. Manzoni, L.; Belvisi, L.; Arosio, D.; Civera, M.; Pilkington-Miksa, M.; Potenza, D.; Caprini, A.; Araldi, E. M. V.; Monferrini, E.; Mancino, M.; Podestà, F.; Scolastico, C. Cyclic RGD-including functionalized azabicycloalkane amino acids as potent integrin antagonists for tumor targeting ChemMedChem 2009, 4, 615-632 and references cited therein.
51. Fu, Y.; Li, S.; Zu, Y.; Yang, G.; Yang, Z.; Luo, M.; Jiang, S.; Wink, M.; Efferth, T. Medicinal chemistry of paclitaxel and its analogues Curr. Med. Chem. 2009, 16, 3966-3985
52. Recently, a azabicycloalkane-RGD bound to paclitaxel via a cleavable diglycolyl ester linker at C2′ was reported to provide promising in vitro and in vivo antitumor activity. See the following: Pilkington-Miksa, M.; Arosio, D.; Battistini, L.; Belvisi, L.; De Matteo, M.; Vasile, F.; Burreddu, P.; Carta, P.; Rassu, G.; Perego, P.; Carenini, N.; Zunino, F.; De Cesare, M.; Castiglioni, V.; Scanziani, E.; Scolastico, C.; Casiraghi, C.; Zanardi, F.; Manzoni, L. Design, synthesis and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery Bioconjugate Chem. 2012, 23, 1610-1622
53. Matson, D. R.; Stukenberg, P. T. Spindle poisons and cell fate: a tale of two pathways Mol. Interventions 2011, 11, 141-150
54. Portugal, J.; Mandilla, S.; Bataller, M. Mechanisms of drug-induced mitotic catastrophe in cancer cells Curr. Pharm. Des. 2010, 16, 69-78
55. Roninson, I. B.; Broude, E. V.; Chang, B. D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells Drug Resist. Updates 2001, 4, 303-313
56. Huang, Y.; Dalton, D. R.; Carroll, P. J. The efficient, enantioselective synthesis of aza sugars from amino acids. 1. The polyhydroxylated pyrrolidines J. Org. Chem. 1997, 62, 372-376
57. Webster, K. L.; Maude, A. B.; O'Donnell, M. E.; Mehrotra, A. P.; Gani, D. Design and preparation of serine-threonine protein phosphatase inhibitors based upon the nodularin and microcystin toxin structures. Part 3 J. Chem. Soc., Perkin Trans. 1 2001, 1673-1695
58. Pirrung, M. C.; Shuey, S. W. Photoremovable protecting groups for phosphorylation of chiral alcohols. Asymmetric synthesis of phosphotriesters of (-)-3′,5′-dimethoxybenzoin J. Org. Chem. 1994, 59, 3890-3897
59. Rosenberg, S. H.; Spina, K. P.; Woods, K. W.; Polakowski, J.; Martin, D. L.; Yao, Z.; Stein, H. H.; Cohen, J.; Barlow, J. L.; Egan, D. A.; Tricarico, K. A.; Baker, W. R.; Kleinert, H. D. Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides J. Med. Chem. 1993, 36, 449-459
60. Gu, K.; Bi, L.; Zhao, M.; Wang, C.; Ju, J.; Peng, S. Toward the development of chemoprevention agents. Part 1: Design, synthesis, and anti-inflammatory activities of a new class of 2,5-disubstituted- dioxacycloalkanes Bioorg. Med. Chem. 2007, 15, 6273-6290
61. Humphrey, J. M.; Bridges, R. J.; Hart, J. A.; Chamberlin, A. R. 2,3-Pyrrolidinedicarboxylates as neurotransmitter conformer mimics: enantioselective synthesis via chelation-controlled enolate alkylation J. Org. Chem. 1994, 59, 2467-2472
62. Narukawa, Y.; Juneau, K. N.; Snustad, D.; Miller, D. B.; Hegedus, L. S. Synthesis of optically active β-lactams by the photolytic reaction of imines with optically active chromium carbene complexes. 2. Synthesis of 1-carbacephalothin and 3-ANA relays J. Org. Chem. 1992, 57, 5453-5462
63. Still, W. C.; Kahn, M.; Mitra, A. Rapid chromatographic techniques for preparative separation with moderate resolution J. Org. Chem. 1978, 43, 2923-2925
64. Perego, P.; Romanelli, S.; Carenini, N.; Magnani, I.; Leone, R.; Bonetti, A.; Paolicchi, A.; Zunino, F. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol Ann. Oncol. 1998, 9, 1-8
65. Perego, P.; Giarola, M.; Righetti, S. C.; Supino, R.; Caserini, C.; Delia, D.; Pierotti, M. A.; Miyashita, T.; Reed, J. C.; Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems Cancer Res. 1996, 56, 556-562